Volume 29, Number 7—July 2023
Research
Triplex ELISA for Assessing Durability of Taenia solium Seropositivity after Neurocysticercosis Cure
Nina L. Tang, Theodore E. Nash, Madelynn Corda, Thomas B. Nutman, and Elise M. O’Connell
Table
Demographics of a cohort of neurocysticercosis patients who underwent serial ELISA testing for reactivity to Taenia solium antigens GP50, T24H, and Ts18var3 to assess seropositivity after cure*
| Characteristic |
Value |
|---|---|
| Sex | |
| M | 28 |
| F |
18 |
| Age at cure, y | |
| 19–29 | 15 |
| 30–60 | 30 |
| >60 |
1 |
| Region of birth | |
| Asia | 4 |
| Central America | 29 |
| Mexico | 8 |
| South America | 4 |
| United States |
1 |
| Neurocysticercosis type† | |
| Parenchymal | |
| Single cyst | 3 |
| >1 cyst | 6 |
| Extraparenchymal | |
| Subarachnoid | 28 |
| Ventricular |
9 |
| Total cohort size |
46 |
| Median length of follow-up, y (range) | |
| Parenchymal | 8.5 (4–17.5) |
| Subarachnoid | 6.6 (1.2–16.6) |
| Ventricular | 8.4 (2.6–12.1) |
*Values are no. patients except as indicated. †Patients were classified by their most severe form of disease: subarachnoid, ventricular, then parenchymal.
Page created: May 08, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.